- Conditions
- Sickle Cell, Diabetes, Cancer, Cardiovascular Disease, Genetic Screening
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,061 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Cincinnati, Ohio • Lewisburg, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2521–2544
of 10,850
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Hypertension
- Interventions
- sitaxsentan sodium
- Drug
- Lead sponsor
- Encysive Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cystic Fibrosis
- Interventions
- Denufosol Tetrasodium (INS37217) Inhalation Solution, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 72 more
- Conditions
- Sickle Cell Disease
- Interventions
- InCharge Health mobile application, HU Toolbox mobile application
- Behavioral
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 15 Years to 45 Years
- Enrollment
- 382 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 7
- States / cities
- Augusta, Georgia • Chicago, Illinois • St Louis, Missouri + 4 more
- Conditions
- Primary Immunodeficiency Disease
- Interventions
- NewGam
- Biological
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 2 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 6
- States / cities
- Irvine, California • Centennial, Colorado • Chicago, Illinois + 3 more
- Conditions
- Wilson Disease
- Interventions
- Not listed
- Lead sponsor
- Yale University
- Other
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Orlando, Florida • Houston, Texas + 1 more
- Conditions
- Behcet's Disease, Churg-Strauss Syndrome, Vasculitis, Central Nervous System, Giant Cell Arteritis, Wegener Granulomatosis, Henoch-Schoenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
- Interventions
- Not listed
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Gonadal Dysgenesis, Turner's Syndrome
- Interventions
- cognitive tests and scales
- Behavioral
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- Not listed
- Enrollment
- 950 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1990 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Autosomal Dominant Polycystic Kidney, Overweight and Obesity
- Interventions
- Daily caloric restriction, Standard advice control
- Behavioral · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Phenylketonuria (PKU)
- Interventions
- Pegvaliase, Diet Only
- Drug · Other
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 10 more
- Conditions
- Stargardts, Retinitis Pigmentosa, Age-related Macular Degeneration, Choroideremia, Geographic Atrophy
- Interventions
- Retinal imaging
- Procedure
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2031
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Retinitis Pigmentosa, Choroideremia
- Interventions
- RTx-015
- Genetic
- Lead sponsor
- Ray Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • Orange, California • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Neurofibromatosis 1, Plexiform Neurofibroma
- Interventions
- Cabozantinib Oral Tablet, Selumetinib Oral Capsule
- Drug
- Lead sponsor
- Girish Dhall, MD
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 5 more
- Conditions
- Muscle Tone, Muscle Strength
- Interventions
- Pure Impact
- Device
- Lead sponsor
- Sofwave Medical LTD
- Industry
- Eligibility
- 25 Years to 60 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Eugene, Oregon
- Conditions
- Long QT Syndrome
- Interventions
- Simplified Cascade Screening
- Genetic
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- Not listed
- Enrollment
- 131 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Lancaster, Pennsylvania
- Conditions
- Myotonia Congenita, Paramyotonia Congenita, Myotonic Dystrophy 1
- Interventions
- Ranolazine
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Muscular Dystrophy, Duchenne
- Interventions
- Eteplirsen
- Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 13 Years · Male only
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Gainesville, Florida • Atlanta, Georgia
- Conditions
- Pompe Disease (Late-onset), Glycogen Storage Disease Type II (GSD-II), Acid Maltase Deficiency Disease, Glycogenosis 2
- Interventions
- alglucosidase alfa, Placebo
- Biological · Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Washington D.C., District of Columbia • St Louis, Missouri + 2 more
- Conditions
- Atopic Dermatitis
- Interventions
- Tralokinumab, Caffeine, Warfarin, Omeprazole, Metoprolol, Midazolam Hydrochloride
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • San Diego, California + 5 more
- Conditions
- Psoriasis, Atopic Dermatitis
- Interventions
- Pandel Cream 0.1%
- Drug
- Lead sponsor
- Fougera Pharmaceuticals Inc.
- Industry
- Eligibility
- 3 Months and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 3
- States / cities
- Omaha, Nebraska • Hilton Head Island, South Carolina • Nashville, Tennessee
- Conditions
- Myotonic Dystrophy Type 1
- Interventions
- rhIGF-I/rhIGFBP-3, placebo
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 12
- States / cities
- Orange, California • Sacramento, California • Kansas City, Kansas + 9 more
- Conditions
- Cystic Fibrosis
- Interventions
- SB656933, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 14 more
- Conditions
- Achondroplasia
- Interventions
- Recifercept
- Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 3 Months to 10 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neurofibromatosis 1
- Interventions
- Deoxycholic Acid, Polidocanol, 1064nm Nd:YAG laser, 755nm Alexandrite Laser
- Drug · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts